-
公开(公告)号：WO2019118638A2
公开(公告)日：2019-06-20
申请号：PCT/US2018/065275
申请日：2018-12-12
Applicant: AMGEN INC.
Inventor： RULIFSON, Ingrid , MURRAY, Justin K. , OLLMANN, Michael , HOMANN, Oliver
Abstract: The present invention relates to RNAi constructs for reducing expression of the PNPLA3 gene. Methods of using such RNAi constructs to treat or prevent liver disease, nonalcoholic fatty liver disease (NAFLD) are also described.
-
公开(公告)号：WO2020123508A2
公开(公告)日：2020-06-18
申请号：PCT/US2019/065481
申请日：2019-12-10
Applicant: AMGEN INC.
Inventor： RULIFSON, Ingrid , MURRAY, Justin K. , OLLMANN, Michael , HOMANN, Oliver
IPC: C12N15/113 , C12N9/10 , C12N9/18
Abstract: The present invention relates to RNAi constructs for reducing expression of the PNPLA3 gene. Methods of using such RNAi constructs to treat or prevent liver disease, nonalcoholic fatty liver disease (NAFLD) are also described.
-
公开(公告)号：WO2021247885A2
公开(公告)日：2021-12-09
申请号：PCT/US2021/035730
申请日：2021-06-03
Applicant: AMGEN INC.
Inventor： LIN, Daniel C. H. , OLLMANN, Michael , MURRAY, Justin K. , HERBERICH, Bradley J. , DAS, Amrita , COLLINS, Patrick , HOMANN, Oliver
IPC: C12N15/113 , C12N15/1137 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , C12N2310/3521 , C12N2310/3523 , C12N2310/3525 , C12N2310/3533 , C12Y101/00
Abstract: The present invention relates to RNAi constructs for reducing expression of the HSD17B13 gene. Methods of using such RNAi constructs to treat or prevent liver disease, nonalcoholic fatty liver disease (NAFLD) are also described.
-
公开(公告)号：WO2020123508A3
公开(公告)日：2020-06-18
申请号：PCT/US2019/065481
申请日：2019-12-10
Applicant: AMGEN INC.
Inventor： RULIFSON, Ingrid , MURRAY, Justin K. , OLLMANN, Michael , HOMANN, Oliver
IPC: C12N15/113 , C12N9/10 , C12N9/18
Abstract: The present invention relates to RNAi constructs for reducing expression of the PNPLA3 gene. Methods of using such RNAi constructs to treat or prevent liver disease, nonalcoholic fatty liver disease (NAFLD) are also described.
-
公开(公告)号：WO2022036126A2
公开(公告)日：2022-02-17
申请号：PCT/US2021/045784
申请日：2021-08-12
Applicant: AMGEN INC.
Inventor： MURRAY, Justin K. , ZHANG, Jun , HOMANN, Oliver , LONG, Jason C. , MEADE, Bryan
IPC: C12N15/113 , A61K31/713 , A61K31/7125 , A61P1/16 , C12N15/1137 , C12N2310/14 , C12N2310/315 , C12N2310/317 , C12N2310/332 , C12N2310/343 , C12N2310/346 , C12N2320/11 , C12N2320/30 , C12Q1/6869
Abstract: The present invention relates to RNAi constructs for reducing expression of the MARC1 gene. Methods of using such RNAi constructs to treat or prevent liver fibrosis and fatty liver diseases, such as nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, are also described.
-
Patent Agency Ranking
公开(公告)号：WO2021119034A1
公开(公告)日：2021-06-17
申请号：PCT/US2020/063844
申请日：2020-12-08
Applicant: AMGEN INC.
Inventor： WU, Bin , OLLMANN, Michael , HOMANN, Oliver , CHENG, Yuan
IPC: C12N15/113 , A61K47/54
Abstract: The present invention relates to RNAi constructs for reducing expression of the LPA gene, which encodes apolipoprotein(a), a component of lipoprotein(a) (Lp(a)) particles. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease, peripheral artery disease, stroke, and myocardial infarction, and to reduce serum Lp(a) levels are also described.
-
公开(公告)号：WO2020243702A2
公开(公告)日：2020-12-03
申请号：PCT/US2020/035545
申请日：2020-06-01
Applicant: AMGEN INC.
Inventor： DAS, Amrita , HERBERICH, Bradley J. , MURRAY, Justin K. , HOMANN, Oliver , OLLMANN, Michael , LIN, Daniel C. H.
IPC: C12N15/113 , A61K31/713 , A61P3/06
Abstract: The present invention relates to RNAi constructs for reducing expression of the SCAP gene. Methods of using such RNAi constructs to treat or prevent liver disease, nonalcoholic fatty liver disease (NAFLD) are also described.
-
公开(公告)号：WO2021030613A1
公开(公告)日：2021-02-18
申请号：PCT/US2020/046222
申请日：2020-08-13
Applicant: AMGEN INC.
Inventor： GU, Wei , HARRINGTON, Essa Hu , HOMANN, Oliver
IPC: C12N15/113
Abstract: The present invention relates to RNAi constructs for reducing expression of the SLC30A8 gene. Methods of using such RNAi constructs to treat or prevent disease, such as pre-diabetes or diabetes are also described.
-
公开(公告)号：WO2019118638A3
公开(公告)日：2019-06-20
申请号：PCT/US2018/065275
申请日：2018-12-12
Applicant: AMGEN INC.
Inventor： RULIFSON, Ingrid , MURRAY, Justin K. , OLLMANN, Michael , HOMANN, Oliver
IPC: C12N15/113 , C12N9/10 , C12N9/18
Abstract: The present invention relates to RNAi constructs for reducing expression of the PNPLA3 gene. Methods of using such RNAi constructs to treat or prevent liver disease, nonalcoholic fatty liver disease (NAFLD) are also described.
-
10.发明申请RNAI CONSTRUCTS FOR INHIBITING ASGR1 EXPRESSION AND METHODS OF USE THEREOF 审中-公开RNAi抑制ASGR1表达的构建体及其使用方法
公开(公告)号：WO2018039647A1
公开(公告)日：2018-03-01
申请号：PCT/US2017/048757
申请日：2017-08-25
Applicant: AMGEN INC.
Inventor： OLLMANN, Michael , LI, Yang , ZHANG, Jun , BISWAS, Kaustav , HOMANN, Oliver , MIRANDA, Leslie P. , MURRAY, Justin K. , WU, Bin , YOON, Oh Kyu , ALLEN, John Gordon , NETIROJJANAKUL, Chawita , CHENG, Yuan
IPC: C12N15/113
Abstract: The present invention relates to RNAi constructs for reducing expression of the ASGR1 gene. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease and myocardial infarction, and to reduce serum non-HDL cholesterol levels are also described.
Abstract translation: 本发明涉及用于减少ASGR1基因表达的RNAi构建体。 还描述了使用这种RNAi构建体来治疗或预防心血管疾病（例如冠状动脉疾病和心肌梗塞）并降低血清非HDL胆固醇水平的方法。
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.02 seconds)
